Aura Drugs And Intermediates Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 21-12-2024
- Paid Up Capital ₹ 3.50 Cr
as on 21-12-2024
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.90 Cr
as on 21-12-2024
- Revenue %
(FY 2023)
- Net Worth -177.53%
(FY 2023)
- Total Assets 81.84%
(FY 2023)
About Aura Drugs And Intermediates
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.50 Cr.
The company currently has active open charges totaling ₹13.90 Cr.
Jaykumar Joshi, Dhaval Vankani, Abha Vankani, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24299GJ2021PTC121215
- Company No.
121215
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aura Drugs And Intermediates?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhaval Vankani  | Director | 16-Mar-2021 | Current |
| Jaykumar Joshi | Director | 16-Mar-2021 | Current |
| Abha Vankani | Director | 16-Mar-2021 | Current |
| Nileshkumar Chaudhari | Director | 16-Mar-2021 | Current |
| Vimladevi Shah | Director | 10-Jul-2023 | Current |
Financial Performance of Aura Drugs And Intermediates.
Aura Drugs And Intermediates Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 177.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Aura Drugs And Intermediates?
Unlock access to Aura Drugs And Intermediates's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Mar 2024 | ₹6.95 Cr | Open |
Others Creation Date: 06 Mar 2024 | ₹6.95 Cr | Open |
How Many Employees Work at Aura Drugs And Intermediates?
Aura Drugs And Intermediates has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aura Drugs And Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aura Drugs And Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
